CommentThe fibrosis benefit index for assessment of therapeutic benefit in non-alcoholic steatohepatitis
References (13)
- et al.
Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States
Gastroenterology
(2011) - et al.
Regulatory science and drug approval for alcoholic and nonalcoholic steatohepatitis
Gastroenterology
(2016) - et al.
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies
J Hepatol
(2005) - et al.
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Lancet
(2015) - et al.
Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease
Gastroenterology
(2015) - et al.
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity
Hepatology
(2004)
There are more references available in the full text version of this article.
Cited by (0)
© 2017 Elsevier Ltd. All rights reserved.